Physician profile
Joe A Sheets
NPI 1518919992
$52,187.95
in general payments reported to CMS, 2019-2025
22 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,364 · 2022: $12K · 2023: $7,489 · 2024: $12K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $5,852 · Travel and Lodging: $2,938 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,900.00 |
| Food and Beverage | $5,851.55 |
| Travel and Lodging | $2,938.03 |
| Education | $403.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,451.16 | 2021-2025 | |
| Amgen INC. | $5,803.24 | 2022-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,083.66 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $605.48 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $514.66 | 2021-2025 | |
| Lilly USA, LLC | $359.27 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $337.32 | 2022-2025 | Sotyktu |
| Pfizer INC. | $312.77 | 2021-2025 | |
| Incyte Corporation | $299.03 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $255.74 | 2021-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $245.52 | 2022-2025 | Nemluvio |
| Leo Pharma INC. | $204.83 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $193.47 | 2025 | Bimzelx |
| Genzyme Corporation | $171.04 | 2021-2025 | |
| Almirall LLC | $89.20 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Arcutis Biotherapeutics, INC. | $64.12 | 2023-2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $51.59 | 2022-2023 | Nuzyra |
| Dermavant Sciences, INC. | $22.06 | 2023 | Vtama |
| Organon LLC | $18.08 | 2025 | Vtama |
| Biofrontera INC. | $17.85 | 2022 | |
| Genentech USA, INC. | $7.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.